Alexion price target raised to $215 from $200 at Brean Capital Brean Capital raised its price target on Alexion following the conclusion of reimbursement discussions in France. The firm raises its estimates on the agreement with the French government and continues to see Alexion as a core holding. Shares are Buy rated.
Alexion announces $500M share repurchase program Alexion Pharmaceuticals announced that the company’s board has authorized a new share repurchase program of up to $500M. The new share repurchase program will take effect upon completion of the company’s current program, which has approximately $22M remaining of its previously authorized $400M.